<DOC>
	<DOCNO>NCT00047346</DOCNO>
	<brief_summary>Phase I trial study effectiveness erlotinib treat patient unresectable liver cancer liver dysfunction . Biological therapy erlotinib may interfere growth tumor cell slow growth tumor</brief_summary>
	<brief_title>Erlotinib Treating Patients With Unresectable Liver Cancer Liver Dysfunction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Establish maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) OSI-774 patient unresectable hepatocellular carcinoma ( HCC ) moderate liver dysfunction . II . Establish pharmacokinetic pharmacodynamic profile OSI-774 HCC patient moderate liver dysfunction . SECONDARY OBJECTIVES : I. Assess possible anti-tumor effect OSI-774 patient advance hepatocellular carcinoma term partial response ( PR ) complete response ( CR ) assess tumor shrinkage RECIST criterion . OUTLINE : This dose-escalation study . Patients receive oral erlotinib daily . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm unresectable hepatocellular carcinoma ( HCC ) without extrahepatic metastasis No fibrolamellar HCC No 2 prior therapy HCC , include systemic chemotherapy , chemoembolization , hepatic arterial infusion chemotherapeutic agent , novel agent Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR least 10 mm spiral CT scan Moderate hepatic dysfunction follow : Bilirubin 24 g/dL Albumin &lt; 2.5 g/dL Ascites PT 24 second &gt; upper limit normal ( ULN ) AST/ALT 2.610 time &gt; ULN No known brain metastases No ascites refractory conservative management ( e.g. , sodium restriction 50 mEq/day dietary sodium fluid restriction and/or diuretic ) Performance status ECOG 02 At least 16 week Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 60,000/mm^3 Hemoglobin ≥ 10 g/dL No decompensated liver disease No jaundice No portosystemic encephalopathy ( evidenced confusion , asterixis , significant sleep disturbance , hypothermia le 36º Celsius ) No hyponatremia &lt; 130 mEq/L No portal hypertension bleed esophageal gastric varix within past 3 month Creatinine ≤ 2 mg/dL No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No gastrointestinal tract disease result inability take oral medication requirement IV alimentation No active peptic ulcer disease No abnormalities cornea ( e.g. , dry eye syndrome Sjögren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No significant traumatic injury within past 21 day No uncontrolled concurrent illness would preclude study participation No ongoing active infection No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover At least 4 week since prior radiotherapy recover No prior surgical therapy affect absorption At least 21 day since prior major surgery At least 4 week since prior agent recover No prior epidermal growth factorreceptor target therapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>